Seeking Alpha

Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar

Company to host a webinar to discuss EDIT-301 clinical data on Monday, December 11, at 1:00 p.m. ET Dr. Rabi Hanna from Cleveland Clinic Children’s to present EDIT-301 clinical data at ASH on Monday, ...
Seeking Alpha

Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June

CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (EDIT), a clinical-stage gene editing company, today announced that two abstracts, including one oral presentation and one ...
Business Insider

Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association ...

All patients treated in the RUBY trial are free of vaso-occlusive events post-renizgamglogene autogedtemcel (reni-cel) infusion Patients had early normalization of total hemoglobin with a mean within ...